Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group. Chaturvedi N, et al. Among authors: parving hh. Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25. Lancet. 2008. PMID: 18823656 Clinical Trial.
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Sjølie AK, et al. Among authors: parving hh. Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25. Lancet. 2008. PMID: 18823658 Free article. Clinical Trial.
Dual renin-angiotensin system blockade and kidney disease.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA. Parving HH, et al. J Am Coll Cardiol. 2009 Jul 14;54(3):278-9; author reply 279-80. doi: 10.1016/j.jacc.2009.02.074. J Am Coll Cardiol. 2009. PMID: 19589445 Free article. No abstract available.
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):387-93. doi: 10.1177/1470320311434818. Epub 2012 Feb 14. J Renin Angiotensin Aldosterone Syst. 2012. PMID: 22333485 Free article. Clinical Trial.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121378 Free article. Clinical Trial.
669 results